Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26122776 | 1.00 | GLP1R (0.36) | GLP1R | |
| SCHEMBL31692385 | 0.95 | GLP1R (0.34) | GLP1R | |
| SCHEMBL38651890 | 0.94 | GLP1R (0.35) | GLP1R | |
| SCHEMBL38652284 | 0.93 | GLP1R (0.35) | GLP1R | |
| SCHEMBL21183679 | 0.92 | GLP1R (0.36) | GLP1R | |
| SCHEMBL20014828 | 0.92 | GLP1R (0.33) | GLP1R | |
| SCHEMBL20014818 | 0.90 | GLP1R (0.31) | GLP1R | |
| SCHEMBL28952251 | 0.88 | GLP1R (0.38) | GLP1R | |
| SCHEMBL21175410 | 0.88 | GLP1R (0.38) | GLP1R | |
| SCHEMBL31472076 | 0.87 | GLP1R (0.36) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010981-A | GLP-1 receptor agonism/GLP-1 secretagogue double-target compound | 仁奎医药科技(北京)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4735456-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| EP-4665730-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4638421-A1 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12365682-B2 | Process to make GLP1 RA and intermediates therefor | ELI LILLY AND COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-11492365-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220213130-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20220213130-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| CN-109790161-B | Pyrazolopyridine derivatives having GLP-1 receptor agonist action | 中外制药株式会社 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022048665-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2021155841-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10858356-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-08 | — | — | US | disclosed |
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
| WO-2018056453-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | 中外製薬株式会社 | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | GLP1R 1/4885 |
| US-20220213130-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885 |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | GLP1R 1/4885 |
| US-12365682-B2 | Process to make GLP1 RA and intermediates therefor | GLP1R, GIPR, NPY4R | GLP1R 1/4885 |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | GLP1R 1/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | GLP1R 1/4885 |
| US-11492365-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | GLP1R 1/4885 |
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | GLP1R 1/4885 |
| US-20260055105-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GIPR, GPR119 | GLP1R 1/4885 |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | GLP1R 1/4885 |
| US-10858356-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.